1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Invion Limited

Invion Limited

IVIXF
Invion LimitedUS flagOther OTC
0.04
USD
- -
- -
3.58MMarket Cap
Invion Limited
IVIXF
(Other OTC)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.07
0.06
0.04
0.05
0.06
0.06
- -
Revenue per Share
-19.12
-8.69
-2.04
-1.12
-1.11
-1.7
-0.33
-0.14
-0.13
-0.02
-0.02
-0.03
-0.04
-0.03
-0.09
-0.12
Basic EPS, GAAP
-0.01
-0.03
-0.06
- -
-0.05
-0.03
- -
- -
- -
- -
- -
- -
-0.12
-0.04
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-27.19
-13.69
-5.19
-1.98
-1.7
-2.16
-1.31
-1.22
-0.42
-0.32
0.06
0.04
0.26
0.26
0.19
0.09
Book Value per Share
16.31
10.97
2.22
-0.06
0.05
-0.63
-0.35
-0.05
0.02
0.01
0.01
- -
0.13
0.08
0.02
- -
Tangible Book Value per Share
1
2
3
5
6
8
14
16
38
55
55
55
61
64
64
72
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
4
3
2
3
4
4
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
-305.21
-64.85
-29.52
-67.48
-70.52
-40.16
-147.18
- -
Operating Margin (%)
- -
- -
- -
2
2
1
1
1
1
- -
- -
- -
- -
1
1
5
Depreciation Expense
-17
-14
-6
-5
-7
-13
-4
-2
-5
-1
-1
-1
-2
-2
-6
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
-660.17
-27.41
-27.44
-63.65
-68.09
-39.34
-152.34
- -
Profit Margin (%)
-5
-2
6
4
4
- -
1
-1
1
- -
1
- -
8
5
1
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
14
17
6
11
10
7
6
4
8
5
5
5
20
18
14
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-51.09
-24.81
-10.06
-39.24
-93.01
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.65%
45.29%
-42.85%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
30.01%
76.73%
56.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4
2024
- -
- -
- -
- -
4
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.03
2024
- -
- -
- -
- -
-0.09
2025
- -
- -
- -
- -
-0.12

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
TransCanna Holdings Inc. (TCNAF)
Beijing Beilu Pharmaceutical Co., Ltd (300016.SZ)
EXMceuticals Inc. (EXM.CN)
Amexdrug Corporation (AXRX)
Ortin Laboratories Limited (ORTINLAABS.BO)
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
Business
Invion Limited Invion Limited (ASX:IVX; OTC:IVIXF) is a clinical-stage Australian life sciences company focused on developing Photosoft technology, a next-generation photodynamic therapy (PDT) platform utilizing photosensitizing compounds, oxygen, and light to generate reactive oxygen species for selective cancer cell destruction and immune response activation; core products include the lead candidate INV043, a novel chlorin-based photosensitizer deliverable topically or intravenously for non-melanoma skin cancers, solid tumors such as ovarian, prostate, lung, glioblastoma, esophageal, triple-negative breast, pancreatic, anogenital, and colorectal cancers, as well as atherosclerosis and infectious diseases including periodontal conditions, viruses like Zika, Dengue, SARS-CoV-2, and antibiotic-resistant bacteria such as MRSA; the platform offers theragnostic capabilities for both treatment and imaging with minimal toxicity and synergy with immune checkpoint inhibitors. Founded in 2000 and headquartered in Melbourne, Australia, Invion holds exclusive perpetual licenses and distribution rights from RMW Cho Group for Photosoft in cancer indications across Australia, New Zealand, Asia Pacific (excluding China, Hong Kong, Macau, Taiwan, Japan), North America, and South Korea, with additional rights for infectious diseases in the US, Canada, and expanded Asian territories serving markets of over 3 billion people. Recent developments include the successful completion of a Phase II prostate cancer trial, ongoing Phase I/II non-melanoma skin cancer trial, planned Phase I/II anogenital cancer trial initiation in 2025, global IP extension to 2041 via new Australian patent grants for INV043, GMP-grade manufacturing, share consolidation to reduce overhangs, and capital-raising of up to A$6.8 million in June 2024 through institutional placements and share purchase agreements with Lind Partners; strategic pharma-funded collaborations with Hanlim Pharm for glioblastoma and esophageal cancer programs, Dr.inB for HPV-related indications, and research partnerships with Peter MacCallum Cancer Centre and Hudson Institute of Medical Research advance multiple oncology and infectious disease pipelines without IP dilution.